House passes AHA-supported bills to promote generic drug competition
The House of Representative today passed two AHA-supported bills to promote generic and biosimilar competition in the prescription drug market. The Orange Book Transparency Act (H.R. 1503) and Purple Book Continuity Act (H.R. 1520) would increase the accuracy and transparency of the two databases that guide development decisions for generic and biosimilar manufacturers.
Related News Articles
Headline
The AHA expressed support Nov. 3 for the bipartisan Home Health Stabilization Act (H.R. 5142), legislation that would establish a two-year pause on planned…
Headline
Cigna’s Evernorth division Oct. 27 announced a new, rebate-free pharmacy benefit model, beginning in 2027, that would reduce monthly prescription drug costs by…
Chairperson's File
This week brings the fourth week of the federal government shutdown as Congress has yet to pass legislation to fund the government. This shutdown is a bit…
Headline
The median net launch price for 154 new drugs increased 51% between 2022 and 2024, after accounting for inflation and discounts, according to a report released…
Headline
The government shutdown is expected to continue into next week as the Senate is expected to adjourn Oct. 23 with no plans to vote this weekend. The chamber Oct…
Headline
The National Emerging Special Pathogens Training and Education Center announced Oct. 15 that it will award $37.5 million in grants to 75 hospitals seeking to…